Global Custom Market Research Reports Provider Company

phone

Aslan Pharmaceuticals Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 53
  • Category: Pharmaceuticals
  • Country: Singapore
Summary

Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies. The companys pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslans ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore.

Aslan Pharmaceuticals Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Partnerships 20
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Licensing Agreements 23
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Equity Offering 29
Aslan Pharma Files Registration Statement for Public Offering of American Depositary Shares for USD86.3 Million 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd - Key Competitors 34
Aslan Pharmaceuticals Pte Ltd - Key Employees 35
Aslan Pharmaceuticals Pte Ltd - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Corporate Communications 37
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 37
Product News 38
08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 38
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 39
Product Approvals 40
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 40
Clinical Trials 41
Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 41
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 42
Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 43
Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 44
Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 45
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 46
Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 47
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 48
May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 49
Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 50
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 51
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List Of Tables

List of Tables
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Aslan Pharma Files Registration Statement for Public Offering of American Depositary Shares for USD86.3 Million 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

List Of Figures

List of Figures
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Physiomics plc (Physiomics) is a computational systems biology services company. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from

View Report

Pharmstandard develops, manufactures and distributes pharmaceutical products. The company offers prescription pharmaceuticals and over-the drug (OTC) pharmaceuticals. It also provides active pharmaceutical ingredients and contract manufacturing services. Pharmstandards product portfolio

View Report

Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports